AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03494426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency thoracic sympathectomy
Description: Under fluoroscopic guidance thoracic sympathectomy will be done as follow~1. antroposterior view of upper thoracic vertebrae ,cephalo-caudal adjustment of C - arm until aliment of endplates of T2 and T3~2. oblique view 20 degree under tunnel view RF 10cm 20G 1mm active tip needle is introduced intimately related to vertebral margin~3. the depth of the needle will be determined under lateral fluoroscopic view the needle is advanced step by step hugging the lateral vertebra l margin until the tip of the needle situated at the middle of the vertebral body . RF lesion 2min 80c will be done and needle is rotated 90 degree on both sides and another two lesions will be done at the end of the procedure 2ml of lidocaine and 20mg of triamcinolone will be injected at each level Post procedure analgesic protocol consisted of either increase or decrease, according to intensity of pain by 50 mg pregabalin and 50 mg tramadole and 25 mg tryptazole, individualized for each patient.
Study NCT03494426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin ,tramadol,and tricyclic antidepressants
Description: patient will receive anti neuropathic medications
Study NCT03494426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin ,tramadol,and tricyclic antidepressants
Description: patient will receive anti neuropathic medications
Study NCT02012881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Physical activity during recess, in academic subjects, active transportation and PA home work
Study NCT01213082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24GyE proton and Anti-VEGF
Description: 24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
Study NCT01213082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16GyE and anti-VEGF
Description: 16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
Study NCT01213082 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Irradiation and anti-VEGF
Description: 2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
Study NCT01627691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: * bioprosthetic bovine pericardial aortic valve~* delivery system
Study NCT00253916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic cardiovascular exercise program
Description: Aerobic cardiovascular exercise program
Study NCT00253916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Program
Description: Resistance Exercise Program
Study NCT01244711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
Study NCT02012881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice
Description: Normal curriculum
Study NCT00847756 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Identification of risk factors
Study NCT00847756 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample
Description: venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
Study NCT01342731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: 100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
Study NCT02808429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
Study NCT02808429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 25 mg
Description: Participants received 25 milligrams (mg) of Atacicept once weekly as SC injection during this study up to a maximum of 73.6 weeks.
Study NCT00847756 — intervention group
Intervention type: PROCEDURE
Intervention: collection of middle ear fluid
Description: During routine surgery middle ear fluids are collected per patient.
Study NCT01103622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral tablet od on Day 4
Study NCT01103622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Digoxin
Description: Oral tablet od on Day 4
Study NCT01103622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet bd, step-wise increased dosage
Study NCT04473521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational denture adhesive cream
Description: The denture adhesive application will be controlled by weight (1.00g +/-0.05g) applied to the maxillary denture only.
Study NCT04473521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Super Poligrip Free
Description: The denture adhesive application will be controlled by weight (1.00g +/- 0.05g) applied to the maxillary denture only.
Study NCT02808429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Description: Participants received 75 mg of Atacicept once weekly as SC injection during this study up to a maximum of 74.1 weeks.
Study NCT00666848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
Study NCT00666848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enalapril 5mg
Description: Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
Study NCT00666848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enalapril 10mg
Description: Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
Study NCT00666848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
Study NCT03667014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab treatment
Study NCT01796158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cASBI+cMET
Description: In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
Study NCT01796158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cASBI
Description: In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
Study NCT04278703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Patients will be given a prescription for 15 opioid tablets for post-operative pain
Study NCT04278703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Patients will be given a prescription for 25 opioid tablets for post-operative pain
Study NCT04278703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: Patients will be given a prescription for 35 opioid tablets for post-operative pain
Study NCT04419545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neural network diagnosis algorithm
Description: we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
Study NCT01642550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Description: RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
Study NCT01642550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03985280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency
Description: Under guidance of combined X-ray and ultrasound the nerves will be located . After local anesthetic aplication cooled RF needle will be apply in the objective position. Cooled RF will be performed for 2:30 minutes at 60 º C degrees.
Study NCT03985280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraaticular steroids and local anesthetic injections
Description: Intraaticular steroids and local anesthetic injections
Study NCT03389308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diacerein 1% ointment
Description: Topically apply study medication to lesions identified by the Investigator that require.~treatment
Study NCT01317485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidectomy with end-colostomy
Description: \[OPEN\] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
Study NCT03990285 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Axumin, Intravenous Solution
Description: To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
Study NCT00847756 — intervention group
Intervention type: PROCEDURE
Intervention: nasopharyngeal swab
Description: A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
Study NCT03934710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug will be administered in solution form
Study NCT03934710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serotonin agonist - 13ug
Description: 13ug lysergic acid diethylamide
Study NCT03934710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serotonin agonist - 26ug
Description: 26ug lysergic acid diethylamide
Study NCT03794713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient support tool
Description: The patient support tool, a software app installed on the smart phones plus a wrist connected to the smart phones by Bluetooth. The wrist could monitor the pulse, which was recorded to the app in the smart phone. Meanwhile, the app could inform to patients about the importance of medication, remind on the medicine intake, share the patients' data with themselves, and warn the patients if the wrist don't wear.
Study NCT01709981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later
Study NCT01709981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
Study NCT01195363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine SR
Description: quetiapine SR, dose range 200-600mg, each night QHS for 6mos
Study NCT01195363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: quetiapine sr placebo
Description: quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
Study NCT03017846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: Application of topical cantharidin
Study NCT04584853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
Study NCT04584853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
Description: Standard of care endocrine therapy for a minimum of 5 years from randomisation
Study NCT04584853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
Description: Standard of care endocrine therapy for a minimum of 5 years from randomisation
Study NCT01261546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: * Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~* Ranitidine 5 mg/kg IV, q.d. for 2 days~* Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.
Study NCT01261546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.
Study NCT01737658 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Program
Description: Exercise Program for Obese Adolescents
Study NCT03700970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
Study NCT03700970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular bupivacaine
Description: 20mL of 0.25% bupivacaine injected on each side.
Study NCT01578785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate
Description: Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
Study NCT01796158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cASBI
Description: In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
Study NCT02240342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant into ovarian artery
Description: Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
Study NCT04171271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activating kinesthetic motor imagery training
Description: Participants in the activating kinesthetic motor imagery training group will imagine high effort exercises (e.g. planking, boxing, jumping, squats, push-ups) in the sessions in home using the study audio-video motor imagery script for 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
Study NCT04171271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing kinesthetic motor imagery training
Description: Participants in the relaxing kinesthetic motor imagery training group will imagine relaxing (low effort) exercises (e.g. breathing exercises, stretching, body awareness exercises) in home using the study audio-video motor imagery script 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
Study NCT04840966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flavor test
Description: A simplified self-administrable flavor test has been proposted to all the enrolled subjects
Study NCT04840966 — intervention group
Intervention type: OTHER
Intervention: Self-assesment questionnaire
Description: Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to no smell/flavor perception and 10 corresponding to excellent smell/flavor perception.
Study NCT02579161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cephalosporins
Description: Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed
Study NCT02579161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroquinolones
Description: If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance
Study NCT02579161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.
Study NCT02579161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin/Gentamicin
Description: 5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin
Study NCT02609425 — intervention group
Intervention type: DEVICE
Intervention: Stratafix PGA Suture
Description: Subject leak Stricture rates post procedure
Study NCT03443635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The intervention educates subjects through the hands-on cooking and nutrition education classes how to buy, cook, store, and consume healthy foods as an adjunct to healthy activity levels and avoidance of such health risks factors as smoking, excessive alcohol intake, and drug use.
Study NCT01450644 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The Hospital2Home Service
Description: This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
Study NCT02136043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBASE system 1.1 (active treatment)
Study NCT03593174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur Rigid Dressing
Description: Removable Rigid Dressing
Study NCT03593174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic Bandage
Description: Usual modality: Elastic bandage
Study NCT00852410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% lidocaine with 1:100,000 adrenaline
Description: high dose
Study NCT00852410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% lidocaine with 1:200,000 adrenaline
Description: 1% lidocaine with 1:200,000 adrenaline
Study NCT01291108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669
Description: AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
Study NCT01291108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost
Description: bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
Study NCT01291108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost
Description: bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
Study NCT01291108 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost
Description: bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
Study NCT01291108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost vehicle
Description: bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
Study NCT01291108 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost vehicle
Description: bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
Study NCT00700648 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Intravenous NovoRapid dose \& frequency as decided by treating physician
Study NCT00641732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
Study NCT00641732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 80 mg, tablets, orally, once daily for up to 10 days.